TNFRSF1A and BAG4

  • Number of citations of the paper that reports this interaction (PMID 9915703)
  • 58
  • Data Source:
  • HPRD (in vivo, in vitro, two hybrid)

TNFRSF1A

BAG4

Gene Name tumor necrosis factor receptor superfamily, member 1A BCL2-associated athanogene 4
Image
Gene Ontology Annotations Cellular Component
Molecular Function
Biological Process
Pathways
Drugs
Diseases
GWAS
  • Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) ( 23648065)
  • Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) ( 23648065)
  • Multiple sclerosis ( 19525953 21833088)
  • Primary biliary cirrhosis ( 21399635)
Protein-Protein Interactions 60 interactors: ADAM17 ATF6 BAG4 BCL10 CASP10 CASP7 CHUK CLIP3 DAPK1 DAXX ERAP1 ERN1 FANCD2 GNB2L1 GRB2 GYS2 HRG HSP90AA1 HSPA8 IKBKB IKBKG JAK1 JAK2 LTA LTB MADD MAGEH1 MAPK1 MOAP1 MYOC NSMAF PIP4K2B PRDX3 PRKCD PSMD2 PTK2 PTPN11 PTPN6 RASSF1 RIPK1 RIPK2 RIPK3 SGTA SRC STAMBP STAT1 SUMO1 SYK TNF TNFRSF25 TNFSF13 TRADD TRAF1 TRAF2 TRAF3 TRAP1 TRPC4AP UBE2I UBQLN1 UCHL1 6 interactors: APOBEC1 BCL2 HSPA1A HSPA8 TNFRSF1A TNFRSF25
Entrez ID 7132 9530
HPRD ID 01861 04861
Ensembl ID ENSG00000067182 ENSG00000156735
Uniprot IDs J9PH39 P19438 O95429
PDB IDs 1EXT 1FT4 1ICH 1NCF 1TNR 1M62 1M7K
Enriched GO Terms of Interacting Partners?
Tagcloud ?
casp3  cl  coincided  corpora  cyclic  disaggregation  estrous  extrinsic  fas  fasl  faslg  fos  ifng  ifngamma  jun  lutea  luteal  luteolysis  luteolytic  p4  pgf2alpha  postmortem  pregnancy  proportions  tnfa  tnfr2  viable 
adenocarcinoma  aid  alk  braf  clinicopathologic  define  differentiated  druggable  fgfr  fgfr1  fgfr2  fgfr3  fibroblast  fourteen  fusion  fusions  harbored  kras  needs  nsclc  relapse  ret  ros1  screened  smokers  subset  tacc3  tendency  verified 
Tagcloud (Difference) ?
casp3  cl  coincided  corpora  cyclic  disaggregation  estrous  extrinsic  fas  fasl  faslg  fos  ifng  ifngamma  jun  lutea  luteal  luteolysis  luteolytic  p4  pgf2alpha  postmortem  pregnancy  proportions  tnfa  tnfr2  viable 
adenocarcinoma  aid  alk  braf  clinicopathologic  define  differentiated  druggable  fgfr  fgfr1  fgfr2  fgfr3  fibroblast  fourteen  fusion  fusions  harbored  kras  needs  nsclc  relapse  ret  ros1  screened  smokers  subset  tacc3  tendency  verified 
Tagcloud (Intersection) ?